References

  1. Wang SL, Ohrmund LC, Hauenstein SI, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
    J Immunol Methods. 2012; in press.
  2. 565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). Brian G. Feagan, Sharat Singh, Steven Lockton, Scott Hauenstein, Linda Ohrmund, Lisa J. Croner, Gordon R. Greenberg, William J. Sandborn, Paul J. Rutgeerts, Severine Vermeire. Gastroenterology, Volume 142, Issue 5, Supplement 1, May 2012, Page S-114.
  3. Sa2047 Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome in Acute Ulcerative Colitis. Sanjay Murthy, David Kevans, Cynthia H. Seow, Alvin Newman, A. Hillary Steinhart, Mark S. Silverberg, Gordon R. Greenberg. Gastroenterology, Volume 142, Issue 5, Supplement 1, May 2012, Page S-388.
  4. Sa2037 New Assay to Detect Infliximab Levels and Anti-Infliximab Antibodies From a Single Serum Sample is Useful in Measuring Efficacy of Treatment With Infliximab in Children With IBD. Gabor Veres, Jess L. Kaplan, Elisabeth De Greef, Emil Chuang, Doloresz Szabo, Kriszta Molnar, Linda Ohrmund, Scott Hauenstein, Sharat Singh, Andras Arato, Gigi Veereman, Harland S. Winter. Gastroenterology, Volume 142,
    Issue 5, Supplement 1, May 2012, Page S-386.
  5. Sa2031 Accelerated Clearance of Serum Infliximab During Induction Therapy for Acute Ulcerative Colitis is Associated With Treatment Failure. David Kevans, Sanjay Murthy, Anna Iacono, Mark S. Silverberg, Gordon R. Greenberg. Gastroenterology, Volume 142, Issue 5, Supplement 1, May 2012, Pages S-384-S-385.
  6. 563 Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated With Infliximab Maintenance Therapy. Niels Vande Casteele, Lize Cuypers, Sharat Singh, Linda Ohrmund, Scott Hauenstein, Gert Van Assche, Paul J. Rutgeerts, Ann Gils, Severine Vermeire. Gastroenterology,
    Volume 142, Issue 5, Supplement 1, May 2012, Page S-114.
  7. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133-1139.
  8. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248-1254.
  9. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608.
 
©2017 Société des Produits Nestlé S.A. Vevey, Switzerland.  All rights reserved.
A Nestlé Health Science Company